DARIEN, Conn.--(BUSINESS WIRE)--Extended Delivery Pharmaceuticals, LLC (EDP) announces that data regarding its lead development candidate SIA-II Insulin will be published in the new issue of Proceedings of the National Academy of Sciences of the USA. The manuscript describes multiple studies in vivo, in several species, demonstrating that a single injection of SIA-II maintains tight glucose control for over 140 days. SIA-II (Supramolecular insulin assembly -II) is a novel form of insulin.
